| Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1475 | 2015 |
| Next-generation sequencing for cancer diagnostics: a practical perspective C Meldrum, MA Doyle, RW Tothill Clin Biochem Rev 32 (4), 177-195, 2011 | 580 | 2011 |
| CONTRA: copy number analysis for targeted resequencing J Li, R Lupat, KC Amarasinghe, ER Thompson, MA Doyle, GL Ryland, ... Bioinformatics 28 (10), 1307-1313, 2012 | 372 | 2012 |
| Genomic-scale prioritization of drug targets: the TDR Targets database F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ... Nature reviews Drug discovery 7 (11), 900-907, 2008 | 355 | 2008 |
| Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles ER Thompson, MA Doyle, GL Ryland, SM Rowley, DYH Choong, ... PLoS Genet 8 (9), e1002894, 2012 | 254 | 2012 |
| Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. SM Hunter, MS Anglesio, GL Ryland, R Sharma, YE Chiew, SM Rowley, ... Oncotarget 6 (35), 37663-37677, 2015 | 206 | 2015 |
| Identification of attractive drug targets in neglected-disease pathogens using an in silico approach GJ Crowther, D Shanmugam, SJ Carmona, MA Doyle, C Hertz-Fowler, ... PLoS Negl Trop Dis 4 (8), e804, 2010 | 192 | 2010 |
| Loss of heterozygosity: what is it good for? GL Ryland, MA Doyle, D Goode, SE Boyle, DYH Choong, SM Rowley, J Li, ... BMC medical genomics 8 (1), 1, 2015 | 160 | 2015 |
| Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors GL Ryland, SM Hunter, MA Doyle, F Caramia, J Li, SM Rowley, M Christie, ... Genome medicine 7 (1), 1-12, 2015 | 158 | 2015 |
| RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary GL Ryland, SM Hunter, MA Doyle, SM Rowley, M Christie, PE Allan, ... The Journal of pathology 229 (3), 469-476, 2013 | 133 | 2013 |
| CDK13 cooperates with CDK12 to control global RNA polymerase II processivity Z Fan, JR Devlin, SJ Hogg, MA Doyle, PF Harrison, I Todorovski, ... Science advances 6 (18), eaaz5041, 2020 | 100 | 2020 |
| Massively parallel sequencing and analysis of the Necator americanus transcriptome C Cantacessi, M Mitreva, AR Jex, ND Young, BE Campbell, RS Hall, ... PLoS Negl Trop Dis 4 (5), e684, 2010 | 91 | 2010 |
| Drug target prediction and prioritization: using orthology to predict essentiality in parasite genomes MA Doyle, RB Gasser, BJ Woodcroft, RS Hall, SA Ralph BMC genomics 11 (1), 222, 2010 | 90 | 2010 |
| LeishCyc: a biochemical pathways database for Leishmania major MA Doyle, JI MacRae, DP De Souza, EC Saunders, MJ McConville, ... BMC systems biology 3 (1), 57, 2009 | 88 | 2009 |
| Central carbon metabolism of Leishmania parasites EC Saunders, DP De Souza, T Naderer, MF Sernee, JE Ralton, MA Doyle, ... Parasitology 137 (9), 1303-1313, 2010 | 76 | 2010 |
| Interfacing Seurat with the R tidy universe S Mangiola, MA Doyle, AT Papenfuss Bioinformatics 37 (22), 4100-4107, 2021 | 59 | 2021 |
| A simple consensus approach improves somatic mutation prediction accuracy DL Goode, SM Hunter, MA Doyle, T Ma, SM Rowley, D Choong, ... Genome med 5 (9), 90, 2013 | 51 | 2013 |
| Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls ER Thompson, KL Gorringe, SM Rowley, MW Wong-Brown, S McInerny, ... Breast Cancer Research 17 (1), 1-11, 2015 | 46 | 2015 |
| Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene M Lefebure, RW Tothill, E Kruse, ED Hawkins, J Shortt, GM Matthews, ... Nature communications 8 (1), 1-10, 2017 | 44 | 2017 |
| The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound J Shortt, AK Hsu, BP Martin, K Doggett, GM Matthews, MA Doyle, J Ellul, ... Cell reports 7 (4), 1009-1019, 2014 | 40 | 2014 |
